Literature DB >> 1509283

Malignant mesothelioma: diagnostic and management strategies for 1992.

N J Vogelzang1.   

Abstract

Malignant mesothelioma of the pleural and peritoneal surfaces is epidemiologically linked to crocidolite, a long, thin, and rigid form of asbestos whose use has been dramatically curtailed within the past 20 to 25 years. The incidence of disease may have peaked around 1984 and may now be declining. The highest incidence of disease occurs in elderly white men (greater than or equal to 75 years old). The histology of mesothelioma is classically biphasic, with both epithelioid and sarcomatous areas present. Independent pathologic review can be useful, and a variety of special stains should be used, if diagnosis is unclear. Electron microscopy and serum carcinoembryonic antigen levels are also useful. Surgical treatments have been difficult, but 3-year survival rates range from 15% to 36%. Unfortunately, only about 20% of all diagnosed patients are candidates for aggressive surgical approaches. Radiotherapy likewise has been disappointing, although occasionally useful. Lastly, 13 single-agent chemotherapy trials conducted on 302 patients using 10 different commercially available drugs have failed to identify a consistently effective agent. Combination chemotherapy has also not proven effective and, therefore innovative new approaches are needed.

Entities:  

Mesh:

Year:  1992        PMID: 1509283

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

Review 1.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

2.  Lymphangitis carcinomatosa complicating primary malignant peritoneal mesothelioma.

Authors:  P S Craft; M S Reading; S Jain; R A O'Neil
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

3.  Current surgical management of malignant pleural mesothelioma.

Authors:  Lambros Zellos; David J Sugarbaker
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

4.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Halil Komek; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2016-04-11       Impact factor: 3.674

Review 5.  Cerebral metastases in pleural mesothelioma: case report and review of the literature.

Authors:  M Wroński; M Burt
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

Review 6.  Peritoneal mesothelioma.

Authors:  Mary E Hesdorffer; John Chabot; Carolyn DeRosa; Robert Taub
Journal:  Curr Treat Options Oncol       Date:  2008-10-08

7.  Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

Authors:  J van Meerbeeck; C Debruyne; N van Zandwijk; P E Postmus; M C Pennucci; F van Breukelen; D Galdermans; H Groen; P Pinson; M van Glabbeke; E van Marck; G Giaccone
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.